People · Operator
Named in public records as an officer, director or promoter · active 2013–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. | — | Pharmaceuticals | Series C | $128.2M | $2.1B | 2019 |
| Dren Bio, Inc. | — | Biotechnology | Series C | $93.1M | $1.3B | 2020 |
| Normunity Holding Company, LLC | — | Biotechnology | Series C | $83.4M | $273.2M | 2022 |
| Crossbow Therapeutics, Inc. | — | Biotechnology | Series B | $67.8M | $128.1M | 2025 |
| Potenza Therapeutics, Inc. | — | Pharmaceuticals | Series B | $35.0M | $170.0M | 2014 |
| Mitokyne, Inc. | — | Pharmaceuticals | Series A | $5.2M | $161.7M | 2013 |
Sakae Asanuma at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sakae Asanuma on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Cordo | 3 | 6 |
| Luke Evnin | 2 | 12 |
| Briggs Morrison | 2 | 8 |
| Alon Lazarus | 2 | 7 |
| Daniel Hicklin | 2 | 4 |
| Todd Foley | 1 | 12 |
| Arnold Oronsky | 1 | 10 |
| Timothy Shannon | 1 | 9 |
| Alex Kolicich | 1 | 8 |
| Alexandra Cantley | 1 | 8 |
| Christoph Westphal | 1 | 8 |
| Derek DiRocco | 1 | 7 |
| Rajeev Dadoo | 1 | 7 |
| Ansbert Gadicke | 1 | 7 |
| Scott Phillips | 1 | 5 |
| Paulina Hill | 1 | 5 |
| Sara Nayeem | 1 | 4 |
| Phil Gutry | 1 | 4 |
| Kazumi Shiosaki | 1 | 4 |
| Chandra Leo | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.